Global End-of-Year Closing Days 2021
As we approach the end of year 2021 holiday season, Cerba Research would like to provide you information related to our operational and courier services. Our labs are closed on the days noted in the downloadable file, please take your shipment transit time into consideration to ensure the sample(s) arrive the day before a Closure Day.
Please download the PDF for more information on our closing days, and how to reach our teams worldwide in case of additional questions.
Conducting Clinical Trials During COVID-19: Lessons for the Next Pandemic
The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola, and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine, and genetic studies.
To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.
Register for this webinar to learn the answers to these questions:
- Did we succeed, how fast did we adapt, and are we ready to face a new pandemic crisis in the future?
- How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?
Webinar: Leveraging Medical Laboratory Data for Patient Recruitment
Connecting real-world laboratory data from clinical sites and digitalizing patient data – the power of Decentralized Clinical Trials (DCT) to change the trials of tomorrow
Digitalization continues to provide an impetus to move away from centralized, high-cost and difficult-to-access settings to more virtual, patient-centric and decentralized clinical trial (DCT) models. Our methods need to be more patient-centric, and we need to collaborate to find remote solutions.
Thanks to digitization, we can now decentralize clinical trials and put patient data in front of research success. In partnership with Biokortex, Cerba Research will show participants of this webinar a picture of the future: how clinical trials will look tomorrow. New technologies allow us to imagine a whole new process for drug development and assays. This new way of thinking reduces costs and enhance access to data. The world is evolving fast, and we need to develop accordingly. Agility, adaptability and digitization need to be the new keywords for a more manageable and secure development.
Watch the recording of our webinar held in April 2021 to learn more!
Cerba Research Global Closing Days 2021
Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development
“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”
– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research
Changing the Shape of Clinical Trials – Interview for FOKUS R&D
Cerba Research is the Belgian division of the French Group Cerba Healthcare. The company facilitates clinical studies and lab tests, and supports the entire logistics chain. What are the developments in this market and what does the future bring? CIO Peter Vermeylen and Lab Manager Joachim Vandroemme explain in this interview for De Standaard FOKUS R&D.
Note: this article has been translated into English. The original Dutch version can be read here.
Presence and Capabilities – Running Clinical Trials in Australia Infographic
The Immense Potential of Africa’s Advantageous Landscape
Whilst not ordinarily making the shortlist for trials in the past, Africa is an emerging as a continent based on its size, demographics, level of economic growth, and desire to improve healthcare and life expectancy. Today, Africa represents over 1.34 billion people and it is expected to surpass two billion people by 2038 and 2.5 billion by 2050. Accounting for over 17% of the global population, representing a diverse population, and carrying the highest disease burden in the world at around 25%, the African continent offers many of the best conditions for conducting clinical trials. Importantly, several diseases – particularly those defined as neglected and tropical – are endemic to the developing world, which includes Africa. Despite all these advantages, Africa contributes to less than 2% of the number of clinical trials.
Africa’s virtual absence from the clinical trials map poses a big problem. The continent displays an incredible amount of genetic diversity. If this diversity is not well represented in clinical trials, the trial findings cannot be generalised to large populations. Genetic analyses have clearly demonstrated that ethnic groups show variable results to various treatments, hence it is imperative to conduct clinical trials in Africa, as Africa suffers more than any other continent from diseases linked to poverty, and the interventions mainly used to cure or treat these diseases from which Africans suffer are designed elsewhere.
Download the article below to continue reading.
Trial by Ordeal of Unprecedented Global Pandemic
Our CEO, Mario Papillon, was interviewed by Clinical Trials Insight on how Cerba Research helps clients receive novel treatments faster, and how our key differentiators have helped us in the fight against COVID-19.
Download the article using the button below, or read a copy on the Clinical Trials Insight website: https://secure.viewer.zmags.com/publication/955cc33c#/955cc33c/18
Covid-19 and its Ripple Effect on Clinical Trials
Our team came together to write an article on Covid-19 and its ripple effect on clinical trials for the Journal for Clinical Studies. Sofie Vandevyver, Daniel Tanner and Mario Papillon discussed the challenges Covid-19 revealed in clinical trials, the overwhelming amount of different assays for the detection of Covid-19 and which ones to use in clinical studies, and what the future of clinical trials might look like.
Download the article using the button below, or read a copy on the Journal for Clinical Studies’ website (https://issuu.com/mark123/docs/2020-jcs-3-june-web_compressed/22).
To find out more about our news, click here